VI 16832 |
| Catalog No.GC32833 |
VI 16832 es un inhibidor de cinasa de tipo I de amplio espectro que se puede utilizar como herramienta de enriquecimiento para el anÁlisis de expresiÓn comparativa de proteÍnas cinasas en diferentes lÍneas de células cancerosas.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1430218-51-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
VI 16832 is a broad spectrum Type I kinase inhibitor which can be used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines.
VI 16832 is a broad spectrum Type I kinase inhibitor[1]. Phosphoproteomics analysis of VI 16832-enriched fractions from MV4-11, HCT116, or 435S cells results in more than 8500 phosphopeptide identifications. These translate into almost 1700 distinct phosphopeptide species derived from 212 different members of the protein kinase superfamily. Analysis of VI 16832-retained proteins from the three cancer cell lines considerably increases the overall number of identified phosphorylation sites on protein kinases. Considering the sum of all phosphopeptide intensities as a measure for VI 16832-enriched protein amount, more than 80% is derived from protein kinases[2].
[1]. Kyla. A. L. Collins, et al. Proteomic Analysis Defines Kinase Taxonomies Specific for Subtypes of Breast Cancer. Apr. 1, 2017. [2]. Felix S. Oppermann, et al. Large-scale Proteomics Analysis of the Human Kinome. Mol Cell Proteomics. 2009 Jul; 8(7): 1751-1764.
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *